GCP
ARIA

GSA Capital Partners’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

GSA Capital Partners’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-60,778
Closed -$832K – 2130
2016
Q3 		$832K Buy
+60,778
New +$610K 0.04% 721
2016
Q2 		– Sell
-12,099
Closed -$77K – 2035
2016
Q1 		$77K Buy
12,099
+1,615
+15% +$9.05K ﹤0.01% 1601
2015
Q4 		$66K Buy
+10,484
New +$68.8K ﹤0.01% 1762
2015
Q3 		– Sell
-26,485
Closed -$219K – 2216
2015
Q2 		$219K Buy
+26,485
New +$234K 0.01% 1779

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

GSA Capital Partners's ARIA Position: Q4 2016 in Review

GSA Capital Partners sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 60,778 shares — an estimated $832K sold.

GSA Capital Partners first reported a position in ARIA in Q2 2015 and held it in 4 quarters. The position peaked at $832K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • GSA Capital Partners reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • GSA Capital Partners sold 60,778 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $832K.
  • GSA Capital Partners first reported a position in Ariad Pharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
  • GSA Capital Partners's Ariad Pharmaceuticals Inc position peaked at $832K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on GSA Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.